公开(公告)号：US20220202930A1

公开(公告)日：2022-06-30

申请号：US17558257

申请日：2021-12-21

Applicant: CureVac AG ,  GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Nicole ROTH ,  Diego Chaves MORENO ,  Hans Wolfgang GROSSE ,  Dominik VAHRENHORST ,  Susanne RAUCH

IPC: A61K39/215 ,  A61P31/14 ,  A61K9/127 ,  A61K47/69 ,  A61K47/60 ,  A61K47/26 ,  C12N7/00

Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

公开(公告)号：US20210260178A1

公开(公告)日：2021-08-26

申请号：US17254847

申请日：2019-06-27

Applicant: CureVac AG

Inventor： Edith JASNY ,  Benjamin PETSCH ,  Hans Wolfgang GROSSE

IPC: A61K39/12 ,  C07K14/005 ,  C12N7/00 ,  A61P31/14

Abstract: The present invention is directed to RNA suitable for use in treatment and/or prophylaxis of an infection with Lassa virus (LASV) or of a disorder related to such an infection. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the RNA, compositions, and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the RNA, compositions and vaccines.